Market Size Estimation:
Top-down approach was used to estimate and validate the total size of the cell isolation market. This method was also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
# The key players in the industry and market have been identified through extensive secondary research
# The revenues generated from the cell isolation products business of leading players have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Projected Revenue Surge, Globally:
According to revenue estimates, the global cell isolation market will be valued $4.4 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 13.4% from 2023 to 2028, when it reaches $8.2 billion. The market’s industry trends are analyzed in the latest research study.
Major Growth Driving Factors:
The market is expanding due to factors like the rise in cell-based research and the growing emphasis on personalized therapy. However, the main things impeding the growth of this market are high cost, safety concerns, and ethical considerations.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479
Data Triangulation:
Following the completion of the market size assessment process, the entire market was divided into a number of segments and sub-segments. Data triangulation and market breakdown processes were used where appropriate to finish the entire market engineering process and yield precise statistics for all segments and subsegments. Through an analysis of numerous variables and patterns from the supply and demand sides, the data was triangulated.
Driver: Government support for cell-based research has increased.
The crucial first stage in the development of cell-based therapies is cell isolation. Because cell-based research has many applications, funding for these kinds of studies has been provided by numerous governments worldwide. The National Institutes of Health (NIH), for example, stated in May 2021 that funding totaling USD 30.0 million will be given to assist research targeted at creating new instruments and technology for researching cells. A number of US universities, including Harvard University, the University of California, San Francisco, and the University of Texas Southwestern Medical Center, received financing. Moreover, the Stem Cell Therapies Mission is investing USD 150.0 million over a ten-year period under the Medical Research Future Fund (MRFF) of the Government.
RESTRAINT: Ethics and safety concerns will impede commercial expansion
The embryo from which the cells are formed must be destroyed in order to isolate the embryonic stem cells. Given that some people believe an embryo to be a potential human person, this creates ethical questions regarding the taking of human life. Teratomas are tumors that comprise cells from all three germ layers, and they can be formed by embryonic stem cells. Without adequate screening, embryonic stem cells put into a patient have the potential to develop into tumors and cause damage. As a result, these elements may hinder market expansion to some degree.
Opportunity: Prospects for expansion in developing economies
The biopharmaceutical sector is expanding quickly in emerging nations like China, India, and Brazil. This is caused by a number of causes, including rising healthcare costs, an aging population, and an increase in chronic illnesses. The necessity for cell separation technologies is driving the development and manufacturing of biopharmaceuticals, as these markets see an increase in demand for these goods. Furthermore, growing markets are funding the creation and use of cutting-edge technologies including flow cytometry, magnetic cell separation, and microfluidics.
As a result, cell isolation procedures are becoming more accurate and efficient, and these technologies are becoming more widely available and reasonably priced in these markets. Additionally, there is an increasing trend in emerging markets for R&D activity. In these areas, public and private organizations are funding research to create novel cures and treatments for long-term illnesses. Since cell isolation is a crucial stage in the creation of various treatments, the market is expanding as a result of the expansion of research efforts in these areas.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=103931479
North America dominated cell isolation market in 2022.
Geographically, the market is divided geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held the greatest market share for cell isolation in 2022, followed by Europe and the Asia-Pacific region. A number of variables, including technical development, expansion of the biotechnology and pharmaceutical industries, and rising incidence of infectious and chronic diseases, account for the major share of the American market.
Leading Companies Operating in This Industry
Key players in the cell isolation market are Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), Terumo Corporation (Japan), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Corning Incorporated (US), F. Hoffmann-La Roche Ltd. (Switzerland), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Alfa Laval (Sweden), Sartorius AG (Germany), Akadeum Life Sciences (US), Bio-Techne (US), PerkinElmer Inc. (US), Invent Biotechnologies, Inc. (US), Takara Bio, Inc. (Japan), MiCareo Inc. (US), Proteintech Group, Inc. (US), QIAGEN (Germany), Lonza (Switzerland), Promega Corporation (US), PluriSelect Life Science UG (Haftungsbeschränkt) & Co. KG (Germany), and MagBio Genomics (US).
